Philogen S.p.A. — Sponsor Intelligence | 21 EU Trials

Filter these 21 trials by condition, phase, country and more.

Open in Search →

21 Registered trials

9 Recruiting

8 Completed trials

7 Countries active

7 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I

Phase I (Other)

Phase III: 3 Phase II: 8 Phase I/II: 2 Phase I: 6 Phase I (Other): 2

100%

8 of 8 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Glioma 3 Basal cell carcinoma 2 Soft tissue sarcoma 2 Rheumatoid arthritis 1 Malignant melanoma stage III 1 Superficial spreading melanoma stage III 1 Squamous cell carcinoma of skin 1

Top IMPs

ONFEKAFUSP ALFA 12 BIFIKAFUSP ALFA 8 DACARBAZINE 1 DOXORUBICIN HYDROCHLORIDE 1 LOMUSTINE 1 PEMBROLIZUMAB 1 TEMOZOLOMIDE 1

All trials

21 total

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence Not authorised

2024-515609-25-00 Phase II 2 countries LOMUSTINE; ONFEKAFUSP ALFA
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus standard temozolomide … Pending

2024-516357-46-00 Phase I/II 2 countries ONFEKAFUSP ALFA; TEMOZOLOMIDE
A phase 2 study of the efficacy of intratumorally administered L19IL2 or L19TNF or L19IL2/L19TNF, all in combination with systemic anti-PD1 … Pending

2024-519326-20-00 Phase II 2 countries BIFIKAFUSP ALFA; ONFEKAFUSP ALFA; PEMBROLIZUMAB
A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors. Pending

2025-522243-17-00 Phase I (Other) 1 country
L19IL2 or L19TNF or L19IL2/TNF in patients with basal cell carcinoma (BCC) Recruiting

2025-523229-16-00 Phase II 4 countries BIFIKAFUSP ALFA; ONFEKAFUSP ALFA
L19IL2/TNF in patients with basal cell carcinoma Recruiting

2025-523230-77-00 Phase II 4 countries BIFIKAFUSP ALFA; ONFEKAFUSP ALFA
L19IL2/L19TNF in patients with cutaneous squamous cell carcinoma Recruiting

2025-523231-19-00 Phase II 4 countries BIFIKAFUSP ALFA; ONFEKAFUSP ALFA
A Phase I study to evaluate the safety and dosimetry of imaging with 68Ga-OncoACP3 in prostate cancer. Recruiting

2025-524594-16-00 Phase I 1 country
A dose-finding Phase I study of F8IL10 intra-articular treatment in Rheumatoid Arthritis Recruiting

2024-517896-19-00 Phase I (Other) 1 country
A phase I study to evaluate the safety and preliminary signs of efficacy of [177Lu]Lu-OncoFAP-23 alone and in combination with L19-IL2 as a … Recruiting

2023-509453-31-00 Phase I 1 country
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients … Recruiting

2022-501822-39-00 Phase I/II 3 countries
Study of the efficacy of intratumoral injections of L19IL2 + L19TNF followed by surgery to prevent or retard appearance of new metastases Recruiting

2023-507119-36-00 Phase III 4 countries BIFIKAFUSP ALFA; ONFEKAFUSP ALFA
Safety and Early Signs of Efficacy of IL12-L19L19 Recruiting

2024-510841-32-00 Phase I 2 countries
L19IL2/L19TNF in skin cancer patients Ended

2024-518531-10-00 Phase II 3 countries BIFIKAFUSP ALFA; ONFEKAFUSP ALFA
Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma Ended

2024-512704-20-00 Phase II 5 countries DACARBAZINE; ONFEKAFUSP ALFA
L19TNF plus doxorubicin in patients with STS Ended

2024-512789-32-00 Phase III 5 countries DOXORUBICIN HYDROCHLORIDE; ONFEKAFUSP ALFA
Neoadjuvant L19IL2/L19TNF- Pivotal study Ended

2024-515749-40-00 Phase III 4 countries BIFIKAFUSP ALFA; ONFEKAFUSP ALFA
A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with CAIX-positive cancer Ended

2024-515607-19-00 Phase I 1 country
A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoACP3 in patients with prostate cancer Ended

2024-515608-38-00 Phase I 1 country
L19IL2/L19TNF in patients with non-melanoma skin cancer. Ended

2024-518530-92-00 Phase II 2 countries BIFIKAFUSP ALFA; ONFEKAFUSP ALFA
A Phase I study to evaluate the safety and dosimetry of 68Ga-labelled OncoFAP derivatives in patients with solid tumors Ended

2022-500902-16-00 Phase I 1 country

Showing 1–21 of 21 trials

← All sponsors A–Z